Janux Therapeutics JANX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's total costs & expenses?
- Janux Therapeutics (JANX) reported total costs & expenses of $37.95M in Q1 2026.
- How has Janux Therapeutics's total costs & expenses changed year-over-year?
- Janux Therapeutics's total costs & expenses increased by 8.7% year-over-year, from $34.9M to $37.95M.
- What is the long-term trend for Janux Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Janux Therapeutics's total costs & expenses has grown at a 46.3% compound annual growth rate (CAGR), from $36.57M to $167.67M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating costs incurred by the company during a specific reporting period, including research and development, general and administrative, and other operational outlays. It serves as a primary measure of the total capital required to sustain the company's ongoing business activities and clinical development programs. Monitoring this figure is essential for assessing the company's burn rate and overall operational efficiency in the absence of significant commercial revenue.